Slide 1: Exchange disclosure cover letter
November 11, 2024 To, To, BSE Limited, Listing Department, 25, P. J. Towers, National Stock Exchange of India Ltd., Dalal Street, Exchange Plaza, Bandra Kurla Complex, Mumbai – 400 001 Bandra (East), Mumbai‐ 400051 Ref: Company Scrip Code: 532834 Ref: Symbol: CAMLINFINE || Series: EQ Sub: In ma on p
Slide 2: Camlin Fine Sciences Limited Investor Presentation – November 2024
Camlin Fine Sciences Limited Investor Presentation – November 2024
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Camlin Fine Sciences Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Performance Highlights – Q2 & H1 FY25
Performance Highlights – Q2 & H1 FY25 3
Slide 5: Q2 FY25 Performance Highlights
Q2 FY25 Performance Highlights Revenue (Rs. In Mn) EBITDA* (Rs. In Mn) PAT (Rs. In Mn) 7.8% 7.2% 10.2% Margin 4,059 4,230 3,959 432 317 284 -208 -347 Q2FY24 Q1FY25 Q2FY25 Q2FY24 Q1FY25 Q2FY25 -1,161 Q2FY24 Q1FY25 Q2FY25 Operational Highlights • Consolidated Revenue improves to Rs. 4,230 mn which is
Slide 6: Operational Revenue Breakup
Operational Revenue Breakup Specialty Ingredients (Rs. In Mn) Specialty Ingredients (Rs. In Mn) Total Specialty Ingredients (Rs. In Mn) (Straights) (Value added blends) 2,005 1,955 4,383 6,338 5,610 3,605 1,030 977 2,229 3,028 3,206 1,997 Q2FY24 Q2FY25 H1FY24 H1FY25 Q2FY24 Q2FY25 H1FY24 H1FY25 Q2FY2
Slide 7: Regional Highlights
Regional Highlights CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) 4,088 2,523 1,546 3,673 2,361 2,203 2,269 1,217 1,206 413 489 188 Q2FY24 Q2FY25 H1FY24 H1FY25 Q2FY24 Q2FY25 H1FY24 H1FY25 Q2FY24 Q2FY25 H1FY24 H1FY25 CFS Brazil (Rs. In Mn) CFS North America (Rs. In Mn) 806 1,615
Slide 8: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs. In Mn) Q2 FY25 Q2 FY24 YoY Q1 FY25 QoQ H1FY24 H1FY24 Revenue from Operation 4,229.7 4,058.8 4.2% 3,958.5 6.9% 8,188.2 8,254.8 Raw material consumption 2,190.7 2,236.1 2,180.4 4,371.1 4,393.9 Employee Cost 522.8 432.4 511.8 1,034.5 870.9 Other exp
Slide 9: Standalone Profit & Loss Statement
Standalone Profit & Loss Statement Particulars (Rs. In Mn) Q2 FY25 Q2 FY24 YoY Q1 FY25 QoQ H1FY24 H1FY24 Revenue from Operation 2,269.1 2,062.1 10.0% 1,819.1 24.7% 4,088.2 3,673.3 Raw material consumption 1,306.2 1,078.2 1,019.9 2,326.2 1,710.4 Employee Cost 196.0 177.0 168.1 364.1 331.8 Other expen
Slide 10: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (Rs. In Mn) Sept – 24 Mar – 24 Particulars (Rs. In Mn) Sept – 24 Mar - 24 Equity Non-Current assets Equity Share Capital 167.5 167.5 Property, Plant and Equipment 5,827.0 7,122.4 Other Equity 6,730.2 8480.0 Capital Work-In-Progress 224.3 455.6 Minority interest
Slide 11: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. In mn) Sept – 24 Sept – 23 Net Profit Before Tax -1,657.9 39.9 Adjustments for: Non-Cash Items / Other Investment or Financial Items 2,565.9 742.9 Operating profit before working capital changes 908.0 782.8 Changes in working capital -82.2 -128.2 Cas
Slide 12: Company Overview
Company Overview INGREDIENTS- Clg Ube
Slide 13: Company Overview
Company Overview FY24 Revenue Mix* ₹ 16,131 mn 26% 100+ 1,250+ Range of Diversified Base of Satisfied Products Customers Worldwide Preferred Partner High Quality & Wide 46% For Customized Shelf-Life Range Solutions Vanillin Manufacturer Among Global 61,000+ Specialty Ingredients Leaders Led by Integ
Slide 14: Global Footprint
Global Footprint 9 Capacity (MTPA) Global Manufacturing 31,000 Facilities Camlin Fine Sciences, India 5 Application Laboratories 6,000 CFS do Brasil 80+ CFS Europe SpA Italy CFS Wanglong Presence in China Countries 12,000 CFS Dresen, Mexico 2 R&D Centres 12,000 CFS Europe SpA, Italy Map not to scale
Slide 15: Product Highlights
Product Highlights FY24 Sales Mix% Key Products End User Industries Key Brands › TBHQ › Pet Food › Animal Feed Mills Straights 26% › BHA › Livestock Nutrition › Biodiesel › Ascorbyl palmitate (ASP) › Food & Beverages › Aquaculture & Fishmeal › Fish Meal › Rendering Specialty Ingredients › 200+ custo
Slide 16: Innovation at Work
Innovation at Work Process Optimization Initiatives • Vanillin Production Optimization: Continuous improvement at our new Dahej plant, refining processes and setting a future – oriented strategic direction • HQ Derivatives Process: Developed a novel, process with improved selectivity for producing H
Slide 17: Acquisition of Vitafor Invest NV
Acquisition of Vitafor Invest NV • Dresen Quimica SAPI De CV, Mexico has acquired 100% stake in Vitafor Invest Acquisition NV, Belgium and its underlying subsidiaries/associate on June 11, 2024 Details • 100% stake in Target Entity for Cash Consideration of € 1 (Euro One) Key Rationale Brief Backgro
Slide 18: Manufactured In-house – Integration Chain
Integration Chain Phenol Hydroquinone Diphenols Catechol Manufactured In-house Performance Performance Specialty Ingredients Chemicals Aroma Ingredients Chemicals Ascorbyl Palmitate1 TBHQ MEHQ Guaiacol Guethol BHA Other derivatives of HQ Veratrole Vanillin Other derivatives of Blends Ethyl Vanillin
Slide 19: ESG
ESG • Main goal by 2030 is to switch to renewable electricity for all manufacturing facilities. Currently, company is exploring different options to achieve this goal Environment • Dedicated to sustainability and done few initiatives from reducing food waste to sourcing clean energy • Constantly see
Slide 20: Board of Directors
Board of Directors Name Profile Ashish Dandekar › Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information Chairman & Managing Director systems, research & development, product development, and marketing › Holds a BA in Economics an
Slide 21: Senior Management Team
Senior Management Team Name › Profile Ashish Dandekar › Over three decades of experience in pharmaceuticals and specialty chemical products including business planning, information Chairman & Managing Director systems, research & development, product development, and marketing › Holds a BA in Econom
Slide 22: Way Forward
Way Forward Specialty Ingredients Aroma Ingredients • Maintaining market leadership for • Introduce specialized and customized Antioxidants products within the vanillin range, catering to diverse application needs • Increasing focus on high margin blends and additives. These formulations are • Activ
Slide 23: Historical Financial Highlights
Historical Financial Highlights
Slide 24: Historical Financial Highlights
Historical Financial Highlights Revenue (Rs. In Mn) EBITDA (Rs. In Mn) PAT (Rs. In Mn) 12.5% 15.3% 10.8% 12.7% 7.0% 2.8% 5.5% 4.3% 2.4% -6.5% Margin 16,816 16,131 14,121 11,871 2,131 654 604 10,168 1,819 298 398 1,528 1,307 1,134 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 -1,049 FY20 FY21 FY2
Slide 25: Operational Revenue Break-Up
Operational Revenue Break-Up Specialty Ingredients (Rs. In Mn) Specialty Ingredients (Rs. In Mn) Total Specialty Ingredients (Rs. In Mn) (Straights) (Value added blends) 11,400 9,679 4,576 7,288 4,111 7,980 3,812 5,103 6,171 2,860 4,168 5,516 2,381 3,135 3,311 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22
Slide 26: Regional Highlights
Regional Highlights CFS India (Rs. In Mn) CFS Mexico (Rs. In Mn) CFS Europe (Rs. In Mn) 7,894 7,733 4,822 4,883 6,855 4,395 5,798 6,000 3,533 3,762 3,198 3,091 2,571 2,735 2,271 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 CFS Brazil (Rs. In Mn) CFS North America (Rs. I
Slide 27: Thank You !
Thank You ! Camlin Fine Sciences Ltd. CIN – L74100MH1993PLCO75361 Mr. Santosh Parab- CFO Email – santosh.parab@camlinfs.com santosh.parab@camlinfs.com www.camlinfs.com www.camlinfs.com http://www.sgapl.net/images/sgapl_logo.jpg Strategic Growth Advisors Pvt. Ltd. CIN - U74140MH2010PTC204285 Mr. Shri